BEIJING, Oct. 29 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that it is scheduled to present at two upcoming investor conferences, including the Oppenheimer 19th Annual Healthcare Conference in New York City and the Credit Suisse Asian Healthcare Conference in Beijing, China.
Ms. Vanessa Wu, Senior Financial Manager, is scheduled to present on Tuesday, November 4, 2008 at 3:20 pm at Oppenheimer 19th Annual Healthcare Conference, at the Waldorf-Astoria Hotel in New York, NY.
Dr. Weidong Yin, Chairman, President and CEO, is scheduled to attend the Credit Suisse Asian Healthcare Conference on November 5 and 6, at The Westin Beijing Hotel at Financial Street in Beijing, China.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: firstname.lastname@example.org.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar
statements. Among other things, the business outlook and quotations from
management in this press release contain forward-looking statements.
Statements that are not historical facts, including statements about
Sinovac's beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. A
number of important factors could cause actual results to differ materially
from those contained in any forward- looking statement. Sinovac does not
undertake any obligation to update any forward-looking statement, except as
required under applicable law.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
The Ruth Group
The Ruth Group
|SOURCE Sinovac Biotech Ltd.|
Copyright©2008 PR Newswire.
All rights reserved